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Edited by Frances ShannonAbstract Tumor necrosis factor alpha (TNF-a) is one of the
best-described cell death promoters. In murine L929 ﬁbroblasts,
dexamethasone inhibits TNF-a-induced cytotoxicity. Since phos-
phatidyl inositol 3 kinase (PI3K) and nuclear factor kappa B
(NF-jB) proteins regulate several survival pathways, we evalu-
ated their participation in dexamethasone protection against
TNF-a cell death. We interfered with these pathways by over-
expressing a negative dominant mutant of PI3K or a non-degrad-
able mutant of inhibitor of NF-jB alpha (IjBa) (the cytoplasmic
inhibitor of NF-jB) in L929 cells. The mutant IjB, but not the
mutant PI3K, abrogated dexamethasone-mediated protection.
The loss of dexamethasone protection was associated with a
diminished accumulation in XIAP and c-IAP proteins.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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L929 cells1. Introduction
Tumor necrosis factor alpha (TNF-a) is a cytokine that in-
duces cell death through speciﬁc receptors (TNF-RI and
TNF-RII) [1–3], the cytotoxicity pathway involves the activa-
tion of caspases 8 and 10 [4]. Parallel to this death signaling
pathway, an antagonist nuclear factor kappa B (NF-jB)-
dependent survival response is activated [5]. The ﬁnal balance
between this two opposing signals determines the fate of the
cells exposed to TNF-a.Abbreviations: TNF-a, tumor necrosis factor alpha; NF-jB, nuclear
factor kappa B; IjB, inhibitor of NF-jB; EMSA, electrophoretic
mobility shift assay; PI3K, phosphatidyl inositol 3 kinase; PAGE,
polyacrylamide gel electrophoresis; Ab, antibody
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doi:10.1016/j.febslet.2005.05.081The TNF-a-mediated cytotoxic eﬀect on L929 is a well char-
acterized model, that involves strong necrotic and apoptotic
components [6]. While TNF-a-dependent cell death is only de-
layed by overexpression of Bcl-2 [7], the synthetic glucocorti-
coid (GC) dexamethasone, confers complete protection
against TNF-a cytotoxicity [8].
Cellular responses to GCs require the formation of an active
complex with the glucocorticoid cytoplasmic receptor (GR)
that modulates transcriptional activity [9], leading to the
expression or repression of a large variety of target genes
[10]. In addition to these direct nuclear eﬀects, dexamethasone
has been shown to promotes cytosolic activation of phosphati-
dyl inositol 3 kinase (PI3K) and Akt proteins associated to dif-
ferent survival pathways [11,12].
Two main pathways of cell survival have been described: one
regulated by NF-jB, and the other by PI3K. Inactive NF-jB is
retained in the cytoplasm bound to inhibitor of NF-jB (IjB)
family members [13]. Upon activation through TNF-a-depen-
dent phosphorylation and ubiquitin-mediated degradation of
the IjB proteins, NF-jB translocates to the nucleus and upreg-
ulates a panel of proteins, including the anti-apoptotic proteins
c-IAP1, c-IAP2 and XIAP [14,15]. Deﬁciencies in NF-jB acti-
vation or inhibition of new protein production render a cell ex-
tremely sensitive to TNF-a [16].
The ability of the PI3K/Akt pathway to suppress apoptosis
has been attributed to both Bad and caspase-9 phosphoryla-
tion [17] as well as to ceramide regulation [18]. In addition
to these anti-apoptotic eﬀects, TNF-a-dependent activation
of Akt can also contribute to cell survival by activating NF-
jB [19].
It has been demonstrated that NF-jB is able to inhibit apop-
tosis triggered by TNF-a [20], and that NF-jB activation by
both, constitutively active PI3K or Akt suppresses TNF-a-
dependent apoptosis of MCF7 and HEK 293 cells [18].
In this study, we have interfered with the PI3K/Akt or the
NF-jB pathways in an attempt to abrogate the protection con-
ferred by dexamethasone against TNF-a-induced cytotoxicity
in L929 cells. While the PI3K/Akt pathway is not involved
in the dexamethasone protection against TNF-a cell death, dis-
ruption of the NF-jB pathway by a non-degradable IjB
mutant abolished the protection conferred by dexametha-
sone. In addition, the loss of dexamethasone protection wasation of European Biochemical Societies.
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and c-IAP proteins.2. Materials and methods
2.1. Cell culture and reagents
Murine L929 cells were obtained from ATCC and subcloned by se-
rial dilutions. We used one speciﬁc clone with high sensitivity to
TNF-a for all experiments [21]. Cells were grown in minimum essen-
tial medium (MEM) supplemented with 1 mM glutamine, 1% (v/v)
penicillin/streptomycin and 10% FBS at 37 C in a humidiﬁed atmo-
sphere with 5% CO2. Cytotoxicity experiments were performed at a
cell density of 20000];cells/cm2 on 10 cm dishes or 48-well plates.
Murine recombinant TNF-a and polyclonal antibody (pAb) against
c-IAP1, XIAP and b-actin were from R&D Systems (Minneapolis,
MN), pAb against phosphorylated and total Akt were from Pharm-
ingen (San Diego, CA). Abs against IjBa, and consensus oligonu-
cleotide for NF-jB were from Santa Cruz Biotechnology (Santa
Cruz, CA). Horseradish peroxidase-conjugated, anti-rabbit IgG,
anti-goat IgG (Zymed, San Francisco, CA), or anti-mouse IgG
(Pierce, Rockford, IL) were used. All other reagents used were ob-
tained from Sigma–Aldrich.2.2. Cell viability assays
Cell viability was evaluated by crystal violet staining as previously
described [22]. Brieﬂy, cells were treated as indicated, and ﬁxed with
1.1% glutaraldehyde at the end of each experiment. After washing
with de-ionized water and air-dried plates were stained with a 0.1%
crystal violet solution. The bound dye was solubilized with 10% ace-
tic acid and quantiﬁed at 590 nm (Bio-Tec Instruments, Winoosky,
VT).0
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Fig. 1. Dexamethasone prevented TNF-a cytotoxicity in L929 cells.
(A) Cell survival of L929 cells stimulated with TNF-a (1 or 5 ng/ml)
for either 24 or 48 h. The percent is in respect with an untreated
control. (B) Cell survival of L929 cells stimulated with TNF-a and
increasing concentrations of dexamethasone (Dex) for 24 h. The
percent is in respect with controls treated with indicated doses of
dexamethasone. *P < 0.05 vs. control.2.3. Expression plasmids and generation of stable transfectants
Plasmids SRa-Dp85 (kindly provided by Dr. W. Ogawa and Dr. M.
Kasuga [23]), containing the cDNA of the dominant-negative mutant
p85a-regulatory subunit of PI3K lacking the p110 binding site, and
pCMV4-IjBa mutant (kindly provided by Dr. Dean Ballard and Dr.
Goeddel [24]), containing ﬂag IjBa with a double point mutation
S32/36-A32/36, were used to subclone the Dp85 or IjBa cDNAs into
pCLNX-GFPN (kindly provided by Dr. C. Ca´rdenas Aguayo, CIN-
VESTAV, Mexico). L929 cells were (3 · 105) were seeded on 6-well
plates 24 h before transfection with 1 lg of the plasmid DNA, using
a calcium phosphate transfection kit (Invitrogen Co., CA) following
the manufacturers instructions. The clones were selected with
2.5 mg/ml G418 (Gibco BRL, Rockville, MD). In both cases, expres-
sion of the recombinant proteins was revealed by Western blot. At
least two stable clones and one control clone with an empty vector
were used in all experiments. Transfection eﬃciency was standardized
according to ﬂuorescence of the GFP.
2.4. Nuclear extract preparation and EMSA
Nuclear translocation of NF-jB was evaluated by electrophoretic
mobility shift assay (EMSA). Cells were stimulated with 1 ng/ml re-
combinant TNF-a for the indicated times and nuclear protein was ob-
tained as described earlier [25]. Protein concentrations were
determined using a commercial Bradford assay (Bio-Rad, Hercules,
CA). EMSA was performed as previously described [26] on 5% poly-
acrylamide gels. Dried gels were exposed to a Storage Phosphor Screen
and scanned with a Storm 850 Phosphorimager (Molecular Dynamics,
San Francisco, CA). Gels were analyzed with the Image Quant soft-
ware (Molecular Dynamics).
2.5. Western blot analysis
Total protein lysates (50 lg) were separated by 10% SDS–polyacryl-
amide gel electrophoresis (PAGE) and transferred to a Hybond-ECL
nitrocellulose membrane (Amersham, Buckinghamshire, UK) as de-
scribed before [25]. Membranes were blocked with 5% skimmed milk
and probed with the indicated Abs. The antigen-antibody complex
was detected by enhanced chemiluminescence (Pierce). Signals were
normalized against b-actin.2.6. Statistical analysis
Data are presented as mean values ± S.E.M. and P values were
determined by unpaired Students t test. All experiments were per-
formed in triplicates and were repeated at least three times. For Wes-
tern blot and EMSA, a representative assay is shown.3. Results
3.1. Dexamethasone confers protection against TNF-a-
cytotoxicity
In L929 cells TNF-a-induced cell death in a dose and time
dependent manner (Fig. 1A). After 24 h of treatment with
1 ng/ml, cell viability fell down to 16%, and by 48 h it was be-
low 2%. At a higher dose (5 ng/ml), the viability decreased to
4% at 24 h and was undetectable by 48 h (Fig. 1A). The treat-
ment of L929 cells with TNF-a (1 ng/ml) and increasing doses
of dexamethasone (0.01–10 lM) for 24 h shown suppression of
the TNF-a-induced cell death in a dose-dependent way (Fig.
2B). Complete protection occurred at 10 lM, even after 72 h
of culture (data not shown).
3.2. The PI3K–Akt signaling pathway is not involved in the
dexamethasone-mediated protection from TNF-a
In order to evaluate the role of the PI3K/Akt pathway in the
protection conferred by dexamethasone against the TNF-a-in-
duced cell death, we used wortmannin [19] or a dominant
Fig. 2. Dexamethasone had no eﬀect on the TNF-a-induced activation
of Akt. (A) Western blot against phosphorylated Akt protein (pAkt)
or b-actin in total lysates of L929 cells exposed to 1 ng/ml of TNF-a
during 1, 5, 10, 20, and 40 min; (B) increasing concentrations of
dexamethasone during 20 min; or (C) co-incubated with 1 ng/ml of
TNF-a at the indicated concentrations of dexamethasone during
20 min.
Fig. 3. Dexamethasone protection against TNF-a-induced cell death
was not mediated by Akt function. (A) Western blot against
phosphorylated (pAkt) or total (tAkt) Akt protein in parental
(L929), or negative dominat (Dp85) expressing cells. Membranes were
stripped and re-blotted when required. When indicated cells were
treated with 1 lM wortmannin (Wort). The bottom panel (NF-jB)
corresponds to nuclear translocation of NF-jB in Dp85-expressing
cells treated as indicated. Cells were incubated for 20 min with 1 ng/ml
of TNF-a, 10 lM dexamethasone or both. (B) Cell survival with TNF-
a (1 ng/ml) (white bars) or TNF-a plus dexamethasone (10 lM) (black
bars), in parental cell line, in the presence of 1 lM wortmannin (Wort)
or in negative dominat (Dp85) cells, stimulated for 24 h.
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by evaluating the phosphorylation of Akt using phospho-spe-
ciﬁc antibodies. In the parental cell line, TNF-a induced a
transient time-dependent increase in Akt phosphorylation with
a maximal induction (6-fold) at 10 min compared with un-
treated control (Fig. 2A). Addition of dexamethasone alone
or TNF-a plus dexamethasone induced similar Akt phosphor-
ylation levels (Fig. 2B and C) that were lower than the one
induced by TNF-a. In all cases b-actin was used as loading
control.
TNF-a-induced phosphorylation of Akt was completely
blocked in parental cells treated with wortmannin and in
Dp85 expressing cells (Fig. 3A, second and third rows). Inhibi-
tion of Akt phosphorylation by wortmannin or Dp85 expres-
sion, did not aﬀect the nuclear translocation of NF-jB (Fig.
3A, bottom row), neither the protective eﬀect of dexametha-
sone against TNF-a cytotoxicity (Fig. 3B). We assured that
pharmacologically active wortmannin was present even after
24 h of incubation by analyzing its ability to interfere with
TNF-a-dependent Akt phosphorylation. In Dp85 stable trans-
fectants, the amount of NF-jB translocated to the nucleus in
basal conditions and following TNF-a treatment were similar
to those in parental L929 cells (data not shown). These results
suggest that the PI3K/Akt pathway is not relevant for the pro-
tection conferred by dexamethasone against TNF-a-induced
cell death in L929 ﬁbroblasts.3.3. NF-jB signaling pathway is required for dexamethasone
protection against TNF-a-induced cell death
To evaluate the participation of the NF-jB pathway in the
protection conferred by dexamethasone against TNF-a cyto-
toxicity, we blocked nuclear translocation with a non-degrad-
able mutant IjB protein (IjBam). In the parental cell line,
dexamethasone did not aﬀect NF-jB activation either IjBa
degradation (Fig. 4).
In contrast to endogenous IjBa, the IjBam protein was not
degraded after TNF-a stimulus (Fig. 5A), and prevented nu-
clear translocation of NF-jB (Fig. 5B). The overexpression
of IjBam dramatically abrogated the dexamethasone
(10 lM) protection against TNF-a (1 ng/ml), reducing survival
from 100% to 22% at 24 h (Fig. 5C), suggesting that NF-jB
participates in the dexamethasone protection against TNF-a.
Moreover, the expression of the IjBam protein signiﬁcantly
increased cell death mediated by TNF-a, reducing viability
from 19% to 11%. Since dexamethasone on its own had no
eﬀect on NF-jB activation, nor did it aﬀect NF-jB nuclear lev-
els during TNF-a stimulation (Fig. 4), it appears that the
Fig. 4. Dexamethasone had no eﬀect on the TNF-a-induced activation
of NF-jB. Western blot of IjB (upper panel) or b-actin, and nuclear
translocation of NF-jB (lower panel), in parental cell line treated as
indicated, stimulated for 20 min with 1 ng/ml of TNF-a, 10 lM
dexamethasone or both.
Fig. 5. Dexamethasone protection against TNF-a-induced cell death
requires NF-jB. (A) Western blot of IjBa or b-actin in cells expressing
the mutant form (IjBam), overexpressed and endogenous IjB proteins
are indicated. (B) Nuclear translocation of NF-jB, in parental (ﬁrst
lane) and IjBam cells (lanes 2–5). Cells were stimulated as in Fig. 4.
(C) Cell survival in parental (L929) and IjBam cells treated for 24 h
with TNF-a (1 ng/ml) (white bars) or TNF-a plus dexamethasone
(10 lM) (black bars). *P < 0.01 vs. parental cell line.
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by TNF-a stimulation.
3.4. Loss of dexamethasone protection by NF-jB inactivation
is associated with downregulation of IAP proteins
In an attempt to determine the eﬀect of IjBam expression on
c-IAP and XIAP protein levels we followed their cellular con-
tent by Western blot analysis. Our results shown that TNF-a
induced a time-dependent reduction in both, c-IAP and XIAP
protein levels (Fig. 6), which correlate with the onset of cell
death in L929 cells. Dexamethasone inhibited the reduction
of the IAP protein levels induced by TNF-a (Fig. 6, TNF/
Dex). In contrast, IjBam increased the downregulation of
IAPs induced by TNF-a, even in the presence of dexametha-
sone (Fig. 6).Fig. 6. Inactivation of the NF-jB pathway reduces protein levels of c-
IAP and XIAP. Western blot of c-IAP1, XIAP or b-actin in parental
cells (L929) or IjBam-expressing cells (IjBam) treated as in Fig. 4.
Membranes were stripped and re-blotted when required.4. Discussion
It has been shown that Akt promotes cell survival, and pro-
tects against apoptosis through mechanisms not fully under-
stood. Using pharmacological inhibitors or negative
dominants against PI3K, we found that interfering with the
PI3K/Akt signaling pathway had no eﬀect on the protection
conferred by dexamethasone against TNF-a cytotoxicity on
L929 cells. Interference with the NF-jB signaling pathway
through an IjBam completely eliminated the protective eﬀect
of dexamethasone. Also, the absence of NF-jB activation cor-
related with a marked decrease of the content of the apoptosis
inhibitory proteins (IAPs), suggesting their involvement in this
phenomenon.
In this moment, we cannot distinguish if the protective eﬀect
of dexamethasone against the TNF-a observed in our system,
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discarding a possible combination of both of them.
Participation of the PI3K/Akt pathway in the NF-jB activa-
tion induced by TNF-a is a controversial issue. The diﬀerences
observed in the participation of the PI3K/Akt on the NF-jB
activation could be due to several reasons, including intrinsic
diﬀerences in cell types or lineages. While in some cell types
PI3K/Akt is essential for NF-jB activation [19], in others this
is not required [27]. In another hand, in primary human kerat-
inocytes PI3K/Akt activation occurs without NF-jB nuclear
translocation [28], suggesting that this pathway does not neces-
sary lead to NF-jB activation. This heterogeneity could in-
clude also variations in the concentration of the diﬀerent
elements of the PI3K/Akt pathway, e.g., diﬀerent isoforms of
them or alternative NF-jB activating pathways. In this work,
we showed that NF-jB activation and dexamethasone protec-
tion are independent of PI3K/Akt pathway (Fig. 3A) on L929
cells.
The lack of eﬀect by Dp85 or wortmannin indicates that
down stream events, such as Bax phosphorylation [17], are
not relevant in the protection mechanism of dexamethasone.
It has been shown that the proportion of IKKa vs. IKKb is
a determining factor for the PI3K/Akt-dependent activation
of NF-jB in diﬀerent cell types [29]. In Dp85 cells, the lack
of interference with TNF-a dependent NF-jB activation,
could be explained by a higher proportion of IKKb vs. IKKa
[29].
As mentioned above, NF-jB activation is required for dexa-
methasone-mediated protection and for this reason we decided
to analyze the NF-jB signaling pathway. In support of the
importance of the NF-jB pathway, we observed that the level
of NF-jB activation and degradation of endogenous IjB in
parental L929 cells observed in response to TNF-a plus dexa-
methasone, is remarkably similar to that observed when trea-
ted only with TNF-a (Fig. 4, lanes 4 and 2, respectively,
upper and bottom panels). Although dexamethasone has been
reported to regulate TNF-a receptors in some cell types
[30,31], our results suggest that dexamethasone does not aﬀect
the strength of signaling of TNF-a receptors. We found a link
between dexamethasone protection against TNF-a and TNF-
a-dependent activation of NF-jB that may represents by itself
a protective mechanism, irrespective of the possible regulation
of TNF-a receptors.
Abrogation of the protection promoted by dexamethasone
against the TNF-a-induced cytotoxicity in the presence of Ij-
Bam, correlates with the absence of NF-jB nuclear transloca-
tion (Fig. 5). In support of the importance of NF-jB in the
protection, our results show that L929 cells stably transfected
with mutated IjBa where much more sensitive to the cytotoxic
eﬀect of TNF-a (Fig. 5). Comparing the kinetics of cell death
between wild type and the mutant IjBa cloned cells expressing
the IjBam, the clones died faster and to a greater extent (data
not shown). Taken together, our results suggest that dexa-
methasone protection is dependent on the TNF-a-mediated
activation of the NF-jB signaling pathway.
A likely way for dexamethasone to provide protection is by
strengthening the survival signals. Microarray studies in dexa-
methasone treated cells show expression of a great variety of
genes [32], interestingly, the anti-apoptotic proteins IAP1
and XIAP are induced in the presence of the glucocorticoid
in diﬀerent cell lines [33]. The correlation that we observed be-
tween the cellular content of IAPs and the protection degree inthe presence of dexamethasone, suggest that in this model,
NF-jB activation is required for a dexamethasone dependent
expression of speciﬁc anti-apoptotic molecules. In fact, jB sites
have been identiﬁed in IAP1, IAP2 and XIAP promoters [32].
In cells expressing the IjBam, the enhanced downregulation of
IAP1 and XIAP that persists even in the presence of dexameth-
asone, correlates with the increased susceptibility to TNF-a,
and further supports the notion that NF-jB signaling is essen-
tial to protection conferred by dexamethasone.
The protection conferred by dexamethasone against TNF-a-
cytotoxicity on L929 cells has been used as a model to study
the protective mechanisms involved in steroid hormone depen-
dent tumor resistance, a frequent characteristic in aggressive
forms of breast and prostate cancer.
The requirement of NF-jB for the protection conferred by
dexamethasone against TNF-a-mediated cell death points to-
ward the NF-jB pathway as a possible therapeutic target.
Interference with this signaling pathway could have a beneﬁ-
cial eﬀect in the treatment of hormone-dependent tumors ren-
dering them more susceptible to the eﬀect of endogenous
cytotoxic cytokines.
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